Title
Blood-Based Biomarkers for Minimal Residual Disease Monitoring in Patients Undergoing Surgical Resection for the Treatment of Lung Cancer

Description
Blood‐based biomarkers for minimal residual disease monitoring in patients undergoing curative intent therapy for the treatment of lung cancer

Objective
The purpose of this research study is to determine if a blood test can be developed to detect cancer cells that are leftover in the body or that may come back after having
treatment. We are doing this research because we think a blood test has the potential to be more accurate than a chest x-ray or a CT scan in detecting lung cancer. In addition,
providing a blood sample is a common medical procedure that is less invasive and has a lower risk of side effects than the chest x-rays or CT scans currently used to check for
lung cancer. A more accurate, less risky test to detect cancer cells could also lead to earlier detection and treatment of lung cancer

Treatment NA

Key Eligibility
Subject has recent (within 6 months of enrollment) untreated pathologic diagnosis of primary lung cancer or radiographic imaging with characteristics that are high risk for malignancy without biopsy

Subject scheduled to proceed for curative intent therapy such as radiation or surgery

Hematocrit level of greater than or equal to 32

Subject is male or female, 18 years and older

EXCLUSION:

Neoadjuvant therapy prior to enrollment

Known cancer diagnosis within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers)

Subjects diagnosed with mesothelioma

Applicable Disease Sites
Lung

Participating Institutions
UW Health Eastpark Medical Center : Surgery Coordinator Contact; UW Health University Hospital : Surgery Coordinator Contact